Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 1.00 |
| ▸ | DNER | Q8NFT8 | 2/20 | 0.84 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.81 |
| ▸ | TSPO | P30536 | 1/20 | 0.81 |
| ▸ | BRDT | Q58F21 | 7/20 | 0.77 |
| ▸ | BRD2 | P25440 | 5/20 | 0.77 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.77 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.77 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.77 |
| ▸ | JAK2 | O60674 | 1/20 | 0.77 |
| ▸ | BRD1 | O95696 | 1/20 | 0.77 |
| ▸ | CCL2 | P13500 | 1/20 | 0.77 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.77 |
| ▸ | EP300 | Q09472 | 1/20 | 0.77 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.77 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.77 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.77 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.77 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.77 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19556888 | 1.00 | BRD4 (1.00) | BRD4DNERADORA3TSPOBRDT | |
| SCHEMBL15980842 | 1.00 | BRD4 (1.00) | BRD4DNERADORA3TSPOBRDT | |
| SCHEMBL7480681 | 0.92 | BRD4 (1.00) | BRD4DNERADORA3TSPOBRDT | |
| SCHEMBL881274 | 0.92 | BRD4 (1.00) | BRD4DNERADORA3TSPOBRDT | |
| SCHEMBL873173 | 0.92 | BRD4 (1.00) | BRD4DNERADORA3TSPOBRDT | |
| SCHEMBL17059514 | 0.92 | BRD4 (0.85) | BRD4DNERADORA3TSPOBRDT | |
| Hydrochloric Acid SCHEMBL15900115 | 0.91 | BRD4 (0.98) | BRD4DNERADORA3TSPOBRDT | |
| Hydrochloric Acid SCHEMBL15900132 | 0.91 | BRD4 (0.98) | BRD4DNERADORA3TSPOBRDT | |
| SCHEMBL21501421 | 0.91 | BRD4 (0.84) | BRD4DNERADORA3TSPOBRDT | |
| SCHEMBL17051088 | 0.91 | BRD4 (1.00) | BRD4DNERADORA3TSPOBRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230117831-A1 | MULTI-FUNCTIONAL CHIMERIC MOLECULES | THE BROAD INSTITUTE, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20220135967-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| WO-2019165229-A1 | SMALL MOLECULES FOR INDUCING SELECTIVE PROTEIN DEGRADATION AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| US-9821068-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9750816-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160243247-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. | 2016-08-25 | — | — | US | disclosed |
| US-20160235731-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243247-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | BRD4 687/4885DNER 1938/4885ADORA3 4664/4885 |
| US-20230117831-A1 | MULTI-FUNCTIONAL CHIMERIC MOLECULES | PHAX, PAICS, SARS1 | BRD4 2993/4885DNER 2479/4885ADORA3 4237/4885 |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DBN1, MYCBP, PSMG3 | BRD4 1674/4885DNER 184/4885ADORA3 3982/4885 |
| US-20160235731-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | BRD4 687/4885DNER 1938/4885ADORA3 4664/4885 |
| US-20220135967-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | PSMG3, MYCBP, DBN1 | BRD4 1683/4885DNER 180/4885ADORA3 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.